Diabetes Metab J.  2012 Dec;36(6):460-461. 10.4093/dmj.2012.36.6.460.

Letter: The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone (Diabetes Metab J 2012;36:371-8)

• Kim SY

• KMID: 2174372
• DOI: http://doi.org/10.4093/dmj.2012.36.6.460

Abstract

No abstract available.

MeSH Terms

Thiazolidinediones
Urinary Bladder
Urinary Bladder Neoplasms
Thiazolidinediones

Reference

1. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004. 351:1106–1118.

2. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. American Diabetes Association. European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009. 32:193–203.

3. Yoshimura R, Matsuyama M, Segawa Y, Hase T, Mitsuhashi M, Tsuchida K, Wada S, Kawahito Y, Sano H, Nakatani T. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003. 104:597–602.

4. Tannehill-Gregg SH, Sanderson TP, Minnema D, Voelker R, Ulland B, Cohen SM, Arnold LL, Schilling BE, Waites CR, Dominick MA. Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar. Toxicol Sci. 2007. 98:258–270.

5. Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers. Int J Cancer. 2008. 123:2254–2259.

6. Dormandy J, Bhattacharya M, van Troostenburg. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009. 32:187–202.

7. U.S. Food and Drug Administration. FDA drug safety communication: ongoing safety review of actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure. updated 2010 Sep 17. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm226214.htm.

8. European Medicines Agency. European Medicines Agency recommends new contraindications and warnings for pioglitazone to reduce small increased risk of bladder cancer. updated 2011 Jul 21. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/07/WC500109176.pdf.

9. Zhu Z, Shen Z, Lu Y, Zhong S, Xu C. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2012. 98:159–163.

10. Mamtani R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K, Lewis JD. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst. 2012. 104:1411–1421.

11. Colmers IN, Bowker SL, Johnson JA. Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. 2012. Epub 2012 Oct 4. DOI: 10.1016/j.diabet.2012.06.003.

12. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012. 35:278–280.

13. Papanas N, Maltezos E, Mikhailidis DP. Metformin and cancer: licence to heal? Expert Opin Investig Drugs. 2010. 19:913–917.